Last reviewed · How we verify
Budesonide Turbuhaler 200 µg
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide Turbuhaler 200 µg |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide is an inhaled corticosteroid that acts locally in the lungs to decrease airway inflammation, mucus production, and airway hyperresponsiveness. It binds to glucocorticoid receptors in the cytoplasm of inflammatory cells, translocates to the nucleus, and modulates gene expression to reduce production of inflammatory cytokines and adhesion molecules. This results in decreased recruitment and activation of inflammatory cells in the airways.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Throat irritation
- Oral candidiasis
Key clinical trials
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
- Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma (PHASE3)
- Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients (PHASE3)
- Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients (PHASE3)
- A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women (PHASE4)
- DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide Turbuhaler 200 µg CI brief — competitive landscape report
- Budesonide Turbuhaler 200 µg updates RSS · CI watch RSS
- AstraZeneca portfolio CI